Related references
Note: Only part of the references are listed.A copper chaperone-mimetic polytherapy for SOD1-associated amyotrophic lateral sclerosis
L. McAlary et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2022)
CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background
Jeremy S. Lum et al.
SCIENTIFIC REPORTS (2021)
CuII(atsm) inhibits ferroptosis: Implications for treatment of neurodegenerative disease
Adam Southon et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Proteome Homeostasis Dysfunction: A Unifying Principle in ALS Pathogenesis
Justin J. Yerbury et al.
TRENDS IN NEUROSCIENCES (2020)
Structural Properties and Interaction Partners of Familial ALS-Associated SOD1 Mutants
Jisen Huai et al.
FRONTIERS IN NEUROLOGY (2019)
CuATSM Protects Against the In Vitro Cytotoxicity of Wild-Type-Like Copper-Zinc Superoxide Dismutase Mutants but not Mutants That Disrupt Metal Binding
Natalie E. Farrawell et al.
ACS CHEMICAL NEUROSCIENCE (2019)
The cysteine-reactive small molecule ebselen facilitates effective SOD1 maturation
Michael J. Capper et al.
NATURE COMMUNICATIONS (2018)
CuII(atsm) improves the neurological phenotype and survival of SOD1G93A mice and selectively increases enzymatically active SOD1 in the spinal cord
James B. Hilton et al.
SCIENTIFIC REPORTS (2017)
A molecular chaperone activity of CCS restores the maturation of SOD1 fALS mutants
Enrico Luchinat et al.
SCIENTIFIC REPORTS (2017)
CuATSM efficacy is independently replicated in a SOD1 mouse model of ALS while unmetallated ATSM therapy fails to reveal benefits
Fernando G. Vieira et al.
IBRO REPORTS (2017)
Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SODG93A mice co-expressing the Copper-Chaperone-for-SOD
Jared R. Williams et al.
NEUROBIOLOGY OF DISEASE (2016)
Susceptibility of Mutant SOD1 to Form a Destabilized Monomer Predicts Cellular Aggregation and Toxicity but Not In vitro Aggregation Propensity
Luke McAlary et al.
FRONTIERS IN NEUROSCIENCE (2016)
Copper Homeostasis as a Therapeutic Target in Amyotrophic Lateral Sclerosis with SOD1 Mutations
Eiichi Tokuda et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide
Juan Tamargo et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
SOD1 aggregation in ALS mice shows simplistic test tube behavior
Lisa Lang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Oral Treatment with CuII(atsm) Increases Mutant SOD1 In Vivo but Protects Motor Neurons and Improves the Phenotype of a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis
Blaine R. Roberts et al.
JOURNAL OF NEUROSCIENCE (2014)
Neuroprotective Copper Bis(thiosemicarbazonato) Complexes Promote Neurite Elongation
Laura Bica et al.
PLOS ONE (2014)
Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis
Erin J. McAllum et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2013)
Inhibition of TDP-43 Accumulation by Bis(thiosemicarbazonato)-Copper Complexes
Sarah J. Parker et al.
PLOS ONE (2012)
Fibrillation precursor of superoxide dismutase 1 revealed by gradual tuning of the protein-folding equilibrium
Lisa Lang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Diacetylbis(N(4)-methylthiosemicarbazonato) Copper(II) (CuII(atsm)) Protects against Peroxynitrite-induced Nitrosative Damage and Prolongs Survival in Amyotrophic Lateral Sclerosis Mouse Model
Cynthia P. W. Soon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Amyotrophic lateral sclerosis
Matthew C. Kiernan et al.
LANCET (2011)
Guidelines for accurate EC50/IC50 estimation
J. L. Sebaugh
PHARMACEUTICAL STATISTICS (2011)
SOD1 Mutations Targeting Surface Hydrogen Bonds Promote Amyotrophic Lateral Sclerosis without Reducing Apo-state Stability
Roberth Bystrom et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Dysregulation of intracellular copper trafficking pathway in a mouse model of mutant copper/zinc superoxide dismutase-linked familial amyotrophic lateral sclerosis
Eiichi Tokuda et al.
JOURNAL OF NEUROCHEMISTRY (2009)
Loss of Metal Ions, Disulfide Reduction and Mutations Related to Familial ALS Promote Formation of Amyloid-Like Aggregates from Superoxide Dismutase
Zeynep A. Oztug Durer et al.
PLOS ONE (2009)
Hormesis and medicine
Edward J. Calabrese
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)
SOD1-associated ALS: a promising system for elucidating the origin of protein-misfolding disease
Anna Nordlund et al.
HFSP JOURNAL (2008)
Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in the familial form of amyotrophic lateral sclerosis
Yoshiaki Furukawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
FALS mutations in Cu, Zn superoxide dismutase destabilize the dimer and increase dimer dissociation propensity: A large-scale thermodynamic analysis
Sagar D. Khare et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2006)
The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s)
MA Dorato et al.
REGULATORY TOXICOLOGY AND PHARMACOLOGY (2005)
Impaired extracellular secretion of mutant superoxide dismutase 1 associates with neurotoxicity in familial amyotrophic lateral sclerosis
BJ Turner et al.
JOURNAL OF NEUROSCIENCE (2005)
Structural trends in copper(II) bis(thiosemicarbazone) radiopharmaceuticals
PJ Blower et al.
DALTON TRANSACTIONS (2003)
Decreased metallation and activity in subsets of mutant superoxide dismutases associated with familial amyotrophic lateral sclerosis
LJ Hayward et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
